



































Multiple adverse drug reactions and genetic
polymorphism testing
A case report with negative result
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Abstract
Rationale:Defects in drug metabolic pathways could explain why some patients have a history of multiple adverse drug reactions
(ADR); therefore we aimed to analyze genetic polymorphisms in a patient with multiple ADR related to drugs with a common hepatic
metabolic pathway through CYP2D6.
Patientconcerns:We report a patient with psychosis and hypertension related to amitriptyline, tramadol, and duloxetine within a
2-year period.
Interventions and Outcomes: A pharmacogenetic test was performed to assess the causative role of the CYP2D6 enzyme,
but did not demonstrate a metabolic deficiency.
Lessons:Although negative results in the reported case; typing for cytochrome P450 isoenzyme polymorphisms could be a useful
diagnostic tool in some patients with a history of multiple ADR.
Abbreviations: ADR = adverse drug reactions, EM= extensive metabolizer, IM = intermediate metabolizer, MDIS =multiple drug
intolerance syndrome, PM = poor metabolizer, UM = ultrarapid metabolizer.
Keywords: adverse drug reactions, CYP2D6, drug metabolism, genetic polymorphism, multiple drug intolerance syndrome
1. Introduction
The multiple drug intolerance syndrome (MDIS) is characterized
by adverse drug reactions (ADR) to more than 2 chemically
unrelated drugs, with or without a known immunologic or other
mechanism responsible.[1,2] Its estimated prevalence varies from
2.1% to 4.9% of patients with any history of an ADR, and is
more likely in females with anxiety and patients with other
comorbidities.[3,4] The management of these patients can be
difficult, because reliance on medication avoidance may limit
optimal first-line therapy. The pathogenic of MDIS is complex
and not well understood.[5] Our hypothesis is that patients with
CYP450 enzyme genetic polymorphisms could present with
MDIS, if drugs they used share this common metabolic pathway
and the ADR are related to drug mechanism of action. To our
knowledge, there is little data describing an association between
the metabolic pathways of medications and clinically apparent
MDIS.We describe a case ofMDIS with intolerance to 4 different
nervous system drugs manifested by episodes of drug-associated
psychosis, hypertension, and skin eruption.
2. Case description
The patient reported here is a 56-year-old Caucasian female with
only a medical history of neuropathic pain due to T2-T3
transverse myelitis in treatment with multiple analgesic drugs in
the outpatient Pain Clinic. She started treatment with amitripty-
line 10mg/d, and between 1 and 2 weeks later, she presented
transitory episodes of visual hallucinations, and amitriptyline
was switched to gabapentin (1200mg/d) ceasing the hallucina-
tions. Almost a year later, because the pain persisted, tramadol
(100mg/d) was added to the treatment. One month later, the
visual hallucinations reappeared accompanied by delusional
ideation, leading to a decrease in the dose of tramadol to 50mg/d.
Thereafter, to control the neuropathic pain, the dose of
gabapentin was increased (2200mg/d). Two months later, she
developed a generalized skin rash with itching. Gabapentin was
suspected to be the responsible drug; the dose was reduced to its
previous of 1200mg/d. The rash progressively disappeared
within 2 weeks. The hallucinations and paranoia persisted for
almost a year and the patient had to take a sick leave from work.
At that moment, the patient was evaluated by a psychiatrist who
diagnosed a drug-induced psychotic disorder that required
treatment with olanzapine, and tramadol was stopped as it
was suspected to be related to the psychosis. Her pain was then
controlled with gabapentin 1500mg/d and acetaminophen 1g
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TID. One month later, because of anxiety and depression, the
psychiatrist prescribed duloxetine (30mg/d). Two days later,
she was admitted to the emergency room for symptomatic
hypertension (blood pressure up to 166/105mm Hg) that
normalized with captopril. Duloxetine was switched to escita-
lopram without new ADR and afterward stopped. The psychosis
disappeared after withdrawal of tramadol and temporary
treatment with olanzapine. Currently, the pain is controlled
with gabapentin and acetaminophen, and the hypertension with
enalapril. This case was reported to the Spanish Pharmacovigi-
lance System.
All the ADR (psychosis, hypertension, and skin eruption) fulfill
the criteria of causality: a plausible time between exposure to
drugs and onset of symptoms, the disappearance of these
symptoms following the withdrawal of the drugs and the
evidence in the literature associating the reactions to the drugs.
After applying the Naranjo’s ADR probability algorithm,[6] the
score was 5 points (probable causal association) for tramadol-
induced psychosis, for duloxetine-induced hypertension, and
for gabapentin-induced skin rash; and the score was 4 points
(possible causal association) for amitriptyline-induced psychosis
(Table 1).
Neuropsychiatric effects of tramadol and amitriptyline, as well
as cardiovascular effects of duloxetine could be explained by
their own mechanism of action through binding to opioid
receptors and/or increasing neurotransmitters such as norepi-
nephrine (type A adverse reactions).[7] Unfortunately plasma
concentrations of drugs were not available in this patient.
Because a common hepaticmetabolic pathway throughCYP2D6
was shared by those drugs, a poor metabolism of the CYP2D6
isoenzyme was suspected. Therefore, some of the most common















41) were analyzed by real-time PCR using TaqMan assays
(Table 1), after the informed consent was signed by the patient.
The PCR conditions were a 10-minute pre-incubation at 95°C to
activate the Taq DNA polymerase, followed by 40 cycles of
denaturation at 92°C for 15 seconds and then by primer
annealing and extension for 1minute at 60°C. Moreover,
CYP2D6
∗
5 and CYP2D6 multiplications were analyzed by
XL-PCR as described in detail elsewhere.[8] In addition,CYP2C9
and CYP2C19 genes were also assessed using TaqMan assays
(Table 2). The amplification conditions were the same as for the
CYP2D6 alleles. The results of the pharmacogenetic test revealed
that the patient was homozygous for all the 3 isoenzymes
(wild type).
3. Discussion
As a result, no metabolic deficiencies for CYP2D6 were
confirmed in the pharmacogenetic test. The main reason that
could explain those results could be the limited assessed alleles in
the pharmacogenetic test. Other reasons could be the fact that
other factors influencing the pharmacokinetic of the drug, such as
drug transporters, would be implicated in the occurrence of ADR.
One out of every 15 persons treated with drugs at standard
doses may have either no therapeutic response or an exaggerated
response to the pharmacological treatment leading to an ADR.
Some of this variability could be explained by CYP450 enzymes
genetic polymorphisms.[9] The different allelic variants translate
into 4 major enzyme hydroxylation capacity groups: poor
metabolizer (PM), intermediate metabolizer (IM), extensive
metabolizer (EM), and ultrarapid metabolizer (UM).[10] About
7% to 10% of European Caucasian population is PMs, and
about 5% of Spaniards are UMs.[11,12] In those cases, the
pharmacogenetic test can elucidate the problem related to the
therapeutic response. Recently, a Pharmacogenetic Decision
Table 1
Characteristics of the adverse drug reactions (ADR).
ADR Involved drug Drug metabolic pathway Naranjo algorithm score ADR treatment
Psychosis Amitriptyline CYP2D6, CYP2C19 4 (possible) —
Tramadol CYP2D6, CYP3A4 5 (probable) Olanzapine
Hypertension Duloxetine CYP2D6, CYP1A2 5 (probable) Captopril or enalapril
Skin eruption Gabapentin Not hepatic metabolism 5 (probable) —
Table 2
CYP2D6, CYP2C19, and CYP2C9 alleles studied in this patient.
Gene Allele SNP ID Genetic polymorphism Enzyme activity TaqMan SNP genotyping assay
CYP2D6 CYP2D6
∗
2 rs1080985 1584C>G Normal C__32407252_30
CYP2D6
∗
3 rs35742686 2549delA Null C__32407232_50
CYP2D6
∗
4 rs1065852; rs3892097 100C>T; 1846G>A Null C__11484460_40; C__27102431_D0
CYP2D6
∗
5 – CYP2D6 deletion Null –
CYP2D6
∗
6 rs5030655 1707delT Null C__32407243_20
CYP2D6
∗
10 rs1065852 100C>T Reduced C__11484460_40
CYP2D6
∗
35 rs1080985; 1584C>G; 31G>A Normal C__32407252_30; C__27102444_80
CYP2D6
∗





2xN — — Enhanced –
CYP2C9 CYP2C9
∗
2 rs1799853 430C>T Reduced C__25625805_10
CYP2C9
∗
3 rs1057910 1075A>C Very reduced C__27104892_10
CYP2C9
∗
6 hCV32287221 818delA Null C__32287221_20
CYP2C19 CYP2C19
∗
2 rs4244285 681G>A Null C__25986767_70
CYP2C19
∗
4 rs28399504 1A>G Null C__30634136_10
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Algorithm designed to simplify the decision-making of clinicians
about when to perform a pharmacogenetic test has been
proposed, and it can be useful for selecting the right patient
that could benefit from it.[13]
The CYP2D6 is a highly polymorphic isoenzyme with >100
allelic variants and subvariants described. There are ethnic
differences in allele frequencies.[14] About 7% of white persons
and 2% to 7% of black persons are PM of CYP2D6.[5] This
enzyme is known to metabolize as many as 25% of commonly
prescribed drugs, such as antidepressants, antipsychotics,
analgesics, cough suppressants, beta adrenergic blocking agents,
antiarrhythmics, and antiemetics.[9] PM of CYP2D6 have a high
risk for ADR due to progressive accumulation of the drug.[11]
When prodrugs like tramadol and codeine that require activation
by CYP2D6 are used, a lack of this enzyme results in reduced
effectiveness of drug therapy.[11,15]
Amitriptyline, a tricyclic antidepressant, is metabolized by
demethylation through the isoenzyme CYP2C19 to the active
compound nortriptyline and also by CYP2D6 to hydroxyl
metabolites. Nortriptyline then is metabolized by CYP2D6 to an
inactive metabolite.[16] Neuropsychiatric adverse reactions
reported with amitriptyline are anxiety, cognitive dysfunction,
confusion, delusions, disorientation, dizziness, drowsiness,
mania or hypomania, hallucinations, insomnia, lack of concen-
tration, nightmares, restlessness, and sedation.[17]
Tramadol, an opioid agonist receptor, is metabolized primarily
by CYP2D6 to a pharmacologically active metabolite O-
desmethyltramadol, and also by the CYP3A4 isoenzyme. The
variability in therapeutic response is closely related to the
CYP2D6 genotype. A CYP2D6 PM has a worst pain control
because a reduction of metabolism to O-desmethyltramadol
before pain-relieving effects is observed.[9] Psychiatric adverse
reactions of tramadol are frequent (10% of all the ADR). These
are hallucinations, confusion, sleep disturbances, delirium,
anxiety, nightmares, panic attacks, depersonalization, and
paranoia. Tramadol-induced hallucinations have been
described in few case reports that recovered quickly after
withdrawal.[18,19]
Duloxetine, a serotonin-norepinephrine reuptake inhibitor, is
metabolized by theCYP1A2 andCYP2D6 isoenzymes and is also
a moderate inhibitor of the CYP2D6.[20] Because duloxetine
increases the noradrenergic system, it could increase blood
pressure, mainly in patients with previous hypertension.[21]
In the revised literature, only a case report has been identified
examining the influence of genetic polymorphisms in a patient
with multiple ADR related to psychotropic medications. This
patient had drug metabolizing deficiencies for CYP2D6,
CYP2C19, and CYP2C9, suggesting that adverse events were
drug induced.[22]
4. Conclusion
Although pharmacogenetic testing did not demonstrate a
metabolic deficiency in the reported case; we suggest that typing
for cytochrome P450 isoenzyme polymorphisms could be a useful
diagnostic tool in some patients with a history of multiple ADR,
helping physicians to manage pain or other conditions with a
better safety profile drug.
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